Education
About Us
Working with TipRanks
Follow Us
Talis Biomedical (TLIS)
OTHER OTC:TLIS
TLIS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.04 - $9.35
Previous CloseN/A
Volume40.00
Average Volume (3M)104.00
Market Cap
$47.53M
Enterprise ValueN/A
Total Cash (Recent Filing)$59.87M
Total Debt (Recent Filing)$18.80M
Price to Earnings (P/E)―
Beta1.41
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.02
Shares Outstanding1,822,820
10 Day Avg. Volume76
30 Day Avg. Volume104
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Talis Biomedical News
TLIS FAQ
What was Talis Biomedical’s price range in the past 12 months?
Talis Biomedical lowest stock price was $1.04 and its highest was $9.35 in the past 12 months.
What is Talis Biomedical’s market cap?
Talis Biomedical’s market cap is $47.53M.
When is Talis Biomedical’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Talis Biomedical’s earnings last quarter?
Talis Biomedical released its earnings results on Aug 07, 2024. The company reported -$4.856 earnings per share for the quarter, missing the consensus estimate of N/A by -$4.856.
Is Talis Biomedical overvalued?
According to Wall Street analysts Talis Biomedical’s price is currently Overvalued.
Does Talis Biomedical pay dividends?
Talis Biomedical does not currently pay dividends.
What is Talis Biomedical’s EPS estimate?
Talis Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Talis Biomedical have?
Talis Biomedical has 1,822,820 shares outstanding.
What happened to Talis Biomedical’s price movement after its last earnings report?
Talis Biomedical reported an EPS of -$4.856 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Talis Biomedical?
Currently, no hedge funds are holding shares in TLIS
Company Description
Talis Biomedical
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Technical Analysis
Ownership Overview
13.64% Insiders
0.73% Mutual Funds
<0.01% Other Institutional Investors
86.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---